Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on developing oral delivery technologies for drugs that are traditionally administered by injection. Its core work centers on oral insulin and related platform technologies, with development activities conducted through the company and its subsidiaries and joint venture entities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of oral insulin candidates and related clinical and commercialization activities.
Licensing of proprietary oral delivery technology to partners for development use.
Participation in joint ventures formed to advance oral insulin and related assets.
Economic interests in partnered products through royalties or profit-sharing arrangements.
Customers
Oramed’s direct counterparties are typically pharmaceutical and biotechnology partners, rather than end patients, because the company monetizes its technology through development collaborations, licenses, and joint ventures. Its commercial value depends on partners that can fund clinical development, manufacture at scale, and help bring oral formulations to market. In addition, the company may ultimately serve patients with diabetes and other chronic conditions through oral alternatives to injectable therapies.
License or co-develop oral drug delivery assets and share development/commercial economics.
Provide formulation and production capabilities needed to scale oral insulin programs.
End users of oral insulin products if the programs reach commercialization.
Strategy
Oramed’s strategy is centered on advancing oral insulin through partnerships that combine its proprietary technology with external manufacturing and funding. The company also seeks to create value through licensing, royalties, and joint venture structures that can move development risk and capital needs to partners. Its broader portfolio includes investments and contractual interests that may supplement the core oral insulin platform.
Combines proprietary technology with partner manufacturing and funding to progress the lead program.
Licensing and royalty structures can create value without fully funding commercialization internally.
Clinical development and venture formation require ongoing capital support.
Geography
Oramed is headquartered in the United States, but a substantial part of its technology and development history is tied to Israel through licensing, regulatory, and collaboration activities. The company’s partnerships also point to a broader international footprint, including commercialization rights outside the United States for certain products. Geography matters because clinical development, manufacturing, and licensing rights are split across jurisdictions.
Risks
Oramed faces the typical risks of a clinical-stage biotechnology company, including development failure, regulatory delays, and the need for substantial external funding. Its value creation also depends on counterparties honoring joint venture, licensing, and warrant-related obligations, while cross-border trade and policy changes can affect execution. Because the company relies on a small number of programs and partner structures, setbacks in any one arrangement can have an outsized impact.
- Dependence on HTIT and other partnersImpact: HighLikelihood: Medium
The business model relies on counterparties for manufacturing, funding, and commercialization.
Exposure: OraTech JV and licensing arrangements
- Oral insulin development may fail or be delayedImpact: High
Clinical-stage drug candidates can fail on efficacy, safety, or trial design.
Exposure: Lead program and joint venture value
- Financing needs may exceed internal resourcesImpact: High
R&D and clinical programs require ongoing capital before product revenue exists.
Exposure: Company-wide operations
- Trade policy and tariff changes could affect JV executionImpact: MediumLikelihood: Medium
Cross-border economic disruption may delay or complicate partner commitments.
Exposure: Joint venture formation and related obligations
- Monetization of warrants and investments is uncertainImpact: MediumLikelihood: Medium
Value depends on market conditions, contractual performance, and regulatory limits.
Exposure: Scilex warrants and other investments
Accounting
Judgemental itemsRevenue depends on contract terms and timing of performance obligations.
Impact: Can create uneven quarterly revenue recognition
Costs may be incurred by the company or shifted to OraTech under the JV.
Impact: Affects operating expense trend and comparability
Holdings in companies such as Scilex and Alpha Tau may be marked to market or otherwise remeasured.
Impact: Can introduce non-operating gains and losses
Repayment of IIA-related amounts and transfer of funded technology affect cost of revenue.
Impact: Can materially affect gross margin in the period recognized
Similar listed companies
Publicly listed companies with a comparable business focus.
Galmed Pharmaceuticals Ltd.
EOCN · Pharmaceutical Preparations
MIRA Pharmaceuticals, Inc
MIRA · Pharmaceutical Preparations
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Oragenics Inc
OGEN · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026